BioCentury’s analysts look back at a year when innovation was hot, but markets were not, and predict what’ll make news in 2025

BioCentury’s Clinical Report also analyzes the impact of a patient death in Beam’s trial, plus data from Cogent, Disc, Essa and Novo

In BioCentury’s latest Clinical Report, Skysona’s cancer risk comes into focus, GSK’s IL-5 meets in rhinosinusitis, Jasper’s c-Kit improves hives, and more

Decisions about manufacturing and distribution could be make-or-break for drug developers producing their own lead-212 

A focus on first-in-class innovation and solid tumor applications